Cargando…

Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn’s disease

BACKGROUND: Since not all Crohn’s disease (CD) patients respond adequately to ustekinumab therapy, biomarkers could aid to monitor treatment response and optimize therapeutic outcomes. OBJECTIVES: To explore the dynamics of serum biomarker concentrations to monitor the response to ustekinumab treatm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van den Berghe, Nathalie, Alsoud, Dahham, Verstockt, Bram, Vermeire, Séverine, Declerck, Paul, Thomas, Debby
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467236/ https://www.ncbi.nlm.nih.gov/pubmed/37655059 http://dx.doi.org/10.1177/17562848231189110

Ejemplares similares

Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises
por: Alsoud, Dahham, et al.
Publicado: (2022)

Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All
por: Sudhakar, Padhmanand, et al.
Publicado: (2022)

Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
por: Hirayama, Hisashi, et al.
Publicado: (2022)

Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study
por: Hanzel, Jurij, et al.
Publicado: (2021)

Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study
por: Hanzel, Jurij, et al.
Publicado: (2021)

Understanding the Molecular Drivers of Disease Heterogeneity in Crohn’s Disease Using Multi-omic Data Integration and Network Analysis
por: Sudhakar, Padhmanand, et al.
Publicado: (2020)

Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model
por: Aguiar Zdovc, Jurij, et al.
Publicado: (2021)

Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases
por: Verstockt, Bram, et al.
Publicado: (2020)

Integrated analysis of microbe-host interactions in Crohn’s disease reveals potential mechanisms of microbial proteins on host gene expression
por: Sudhakar, Padhmanand, et al.
Publicado: (2022)

Serum Ustekinumab Concentrations Are Associated With Remission in Crohn’s Disease Defined by a Serum-Based Endoscopic Healing Index
por: Walshe, Margaret, et al.
Publicado: (2021)

Ustekinumab Successfully Treats and Maintains Remission of Pyostomatitis Vegetans Associated with Crohn’s Disease
por: Abi Doumeth, Sarah, et al.
Publicado: (2020)

Mucosal IL13RA2 expression predicts nonresponse to anti‐TNF therapy in Crohn's disease
por: Verstockt, Bram, et al.
Publicado: (2019)

New biologics and small molecules in inflammatory bowel disease: an update
por: Sabino, João, et al.
Publicado: (2019)

New treatment options for inflammatory bowel diseases
por: Verstockt, Bram, et al.
Publicado: (2018)

GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD
por: Dierckx, Tim, et al.
Publicado: (2019)

Genetic Influences on the Development of Fibrosis in Crohn’s Disease
por: Verstockt, Bram, et al.
Publicado: (2016)

Distinct transcriptional signatures in purified circulating immune cells drive heterogeneity in disease location in IBD
por: Verstockt, Bram, et al.
Publicado: (2023)

Clinical utility of ustekinumab in Crohn’s disease
por: Kotze, Paulo Gustavo, et al.
Publicado: (2018)

Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020)

Computational Biology and Machine Learning Approaches to Understand Mechanistic Microbiome-Host Interactions
por: Sudhakar, Padhmanand, et al.
Publicado: (2021)

Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease
por: Buisson, Anthony, et al.
Publicado: (2021)

Tofacitinib, two-faced Janus in ulcerative colitis and Crohn’s disease?
por: Biemans, Vince BC, et al.
Publicado: (2020)

Rapid Resolution of Vulvar Crohn's Disease With Ustekinumab
por: Stoleru, Gianna, et al.
Publicado: (2020)

Successful Treatment of Oral Crohn’s Disease by Ustekinumab
por: Jukema, Jelmer B, et al.
Publicado: (2020)

Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
por: Chaparro, María, et al.
Publicado: (2022)

A150 ASSOCIATION BETWEEN SERUM USTEKINUMAB CONCENTRATIONS AND ENDOSCOPIC DISEASE ACTIVITY IN CROHN’S DISEASE
por: Yanofsky, R, et al.
Publicado: (2022)

Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease
por: Verstockt, Sare, et al.
Publicado: (2021)

Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: Results up to Week 104 of the STARDUST trial
por: Panés, Julian, et al.
Publicado: (2023)

Ustekinumab for Successful Treatment of Refractory Esophageal Crohn’s Disease
por: Barkin, Jodie A., et al.
Publicado: (2016)

Metastatic Vulval Crohn’s Disease With Good Outcome on Ustekinumab
por: Lim, Yizhe, et al.
Publicado: (2021)

Molecular Changes in the Non-Inflamed Terminal Ileum of Patients with Ulcerative Colitis
por: Lee, Ho-Su, et al.
Publicado: (2020)

Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab
por: Chen, An-Yu, et al.
Publicado: (2019)

Adalimumab in Crohn’s disease
por: Van Assche, Gert, et al.
Publicado: (2007)

Big data in IBD: big progress for clinical practice
por: Seyed Tabib, Nasim Sadat, et al.
Publicado: (2020)

Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain?
por: Jacobs, Inge, et al.
Publicado: (2021)

Genome‐wide association studies in Crohn's disease: Past, present and future
por: Verstockt, Bram, et al.
Publicado: (2018)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
por: Liu, Eddie Y., et al.
Publicado: (2017)

Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
por: Hansson-Hedblom, Amanda, et al.
Publicado: (2018)

Cost of Refractory Crohn’s Disease Before and After Ustekinumab Utilization
por: Rahme, Elham, et al.
Publicado: (2019)

Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease
por: Cohen, Barrie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cpti8jed4mmrom21hvuhrmlbgv